Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's PerspectiveFRONTIERS IN MEDICINEIF32021-08-273OA
Regulatory Standards in Orphan Medicinal Product Designation in the EUFRONTIERS IN MEDICINEIF32021-06-259OAAI
Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseasesDRUG DISCOVERY TODAYIF7.52020-02-015OAAI
Defining orphan conditions in the context of the European orphan regulation: challenges and evolutionNATURE REVIEWS DRUG DISCOVERYIF101.82018-09-125PREAI
Neuregulin 3 promotes excitatory synapse formation on hippocampal interneurons神经调节蛋白3促进海马中间神经元兴奋性突触形成EMBO JOURNALIF8.32018-07-2654OAAI
Establishing rarity in the context of orphan medicinal product designation in the European UnionDRUG DISCOVERY TODAYIF7.52018-03-019PREAI
Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditionsDRUG DISCOVERY TODAYIF7.52018-01-0110PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向